ClinicalTrials.gov
public full text
Public Domain
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer#851469
- Supplementary Material for: Abemaciclib-associated psychosis: a case report of a rare neuropsychiatric adverse effect during breast cancer treatment#363840
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer#844627
- Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)#871547
- A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer#868231
Record · ID 969713
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive